YCBD vs TLRY vs CGC vs ACB vs XXII

For growth investors, 22nd Century Group, Inc.

(XXII) is the stronger pick with 48. 1% revenue growth year-over-year, versus -9. 5% for Canopy Growth Corporation (CGC). Aurora Cannabis Inc. (ACB) offers the better valuation at 164. 2x trailing P/E, making it the more compelling value choice. Analysts rate Tilray Brands, Inc. (TLRY) a "Hold" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Tilray Brands, Inc.

(TLRY) delivered a total return of -65. 0%, compared to -100. 0% for 22nd Century Group, Inc. (XXII). Over 10 years, the gap is even starker: TLRY returned -74. 7% versus XXII's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), cbdMD, Inc.

(YCBD) is the lower-risk stock at 0. 66β versus Tilray Brands, Inc. 's 2. 03β — meaning TLRY is approximately 206% more volatile than YCBD relative to the S&P 500. On balance sheet safety, Aurora Cannabis Inc. (ACB) carries a lower debt/equity ratio of 17% versus 108% for cbdMD, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), 22nd Century Group, Inc.

(XXII) is pulling ahead at 48. 1% versus -9. 5% for Canopy Growth Corporation (CGC). On earnings-per-share growth, the picture is similar: Aurora Cannabis Inc. grew EPS 102. 2% year-over-year, compared to -651. 7% for Tilray Brands, Inc.. Over a 3-year CAGR, ACB leads at 15. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Aurora Cannabis Inc.

(ACB) is the more profitable company, earning 0. 5% net margin versus -266. 3% for Tilray Brands, Inc. — meaning it keeps 0. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACB leads at 1. 4% versus -277. 9% for TLRY. At the gross margin level — before operating expenses — YCBD leads at 56. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, XXII (100.

0% yield) pays a dividend. YCBD, TLRY, CGC, ACB do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, cbdMD, Inc.

(YCBD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 66)). Tilray Brands, Inc. (TLRY) carries a higher beta of 2. 03 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (YCBD: -100. 0%, TLRY: -74. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (YCBD (Healthcare) and TLRY (Healthcare) and CGC (Healthcare) and ACB (Healthcare) and XXII (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: YCBD is a small-cap quality compounder stock; TLRY is a small-cap quality compounder stock; CGC is a small-cap quality compounder stock; ACB is a small-cap high-growth stock; XXII is a small-cap high-growth stock. XXII pays a dividend while YCBD, TLRY, CGC, ACB do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.